Macrophages, in response to gamma-interferon and LPS, acquire the ability to bind and lyse tumor cells but not normal cells. Amplification of this phenomenon may provide a useful modality for the treatment of cancer. The mechanism by which macrophages acquire tumoricidal ability is poorly understood. Moreover, the components of tumor cell surfaces recognized by macrophages are not known. Considerable data indicate that carbohydrates on tumor cell surfaces participate directly in recognition by macrophages. A major objective of this proposal is to determine if specific carbohydrates which are expressed on the surface as a result of oncogenic transformation are the structures recognized by macrophages. To accomplish this objective, glycopeptides will be purified from tumor cells and from glycoproteins of defined oligosaccharide structure. The ability of these glycopeptides to inhibit tumor cell binding and lysis by activated mouse peritoneal macrophages will be examined. The emphasis of this work will be on correlating inhibitory ability with specific oligosaccharide structural features. The presence of specific receptors on the macrophage surface for carbohydrates which are inhibitory will be assayed for by surface binding studies using iodinated glycopeptides. Should receptors be identified, it will be determined if their surface expression correlates with the acquisition of tumoricidal activity in response to gamma-interferon. Biochemicl data indicate that the surface organization of the ganglioside GM1 and of the neutral glycolipid asialo GM1 is altered by macrophage activation. These changes could be related to the mechanism of activation and could be essential for effective tumor cell interactions. The second major objective of this proposal is to study the behavior of macrophage glycolipids in more detail. Cytochemical studies will be performed to determine if the biochemical data reflect changes in glycolipid surface distribution or intracellular localization. To assess the importance of gangliosides and neutral glycolipids in the development of tumoricidal activity, GM1 and asialo GM1 will be removed (""""""""modulated"""""""") from the apical surface by plating macrophages on surfaces coated with choleragenoid and anti-asialo GM1 antibodies. The ability of these macrophages to respond to Gamma-interferon, and to bind and lyse tumor cells will be examined. This method will also be used to determine if GM1 and asialo GM1 associate with specific proteins on the macrophage surface.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA042276-01
Application #
3183330
Study Section
Experimental Immunology Study Section (EI)
Project Start
1986-09-01
Project End
1989-08-31
Budget Start
1986-09-01
Budget End
1987-08-31
Support Year
1
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02215
Henderson, Barbara W; Gollnick, Sandra O; Snyder, John W et al. (2004) Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res 64:2120-6
Shaw, L M; Mercurio, A M (1995) Regulation of alpha 6 beta 1 integrin-mediated migration in macrophages. Agents Actions Suppl 47:101-6
Shaw, L M; Turner, C E; Mercurio, A M (1995) The alpha 6A beta 1 and alpha 6B beta 1 integrin variants signal differences in the tyrosine phosphorylation of paxillin and other proteins. J Biol Chem 270:23648-52
Shaw, L M; Mercurio, A M (1994) Regulation of cellular interactions with laminin by integrin cytoplasmic domains: the A and B structural variants of the alpha 6 beta 1 integrin differentially modulate the adhesive strength, morphology, and migration of macrophages. Mol Biol Cell 5:679-90
Lotz, M M; Andrews Jr, C W; Korzelius, C A et al. (1993) Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci U S A 90:3466-70
Shaw, L M; Lotz, M M; Mercurio, A M (1993) Inside-out integrin signaling in macrophages. Analysis of the role of the alpha 6A beta 1 and alpha 6B beta 1 integrin variants in laminin adhesion by cDNA expression in an alpha 6 integrin-deficient macrophage cell line. J Biol Chem 268:11401-8
Messier, J M; Shaw, L M; Chafel, M et al. (1993) Fimbrin localized to an insoluble cytoskeletal fraction is constitutively phosphorylated on its headpiece domain in adherent macrophages. Cell Motil Cytoskeleton 25:223-33
Shaw, L M; Mercurio, A M (1993) Regulation of alpha 6 beta 1 integrin laminin receptor function by the cytoplasmic domain of the alpha 6 subunit. J Cell Biol 123:1017-25
Lee, E C; Lotz, M M; Steele Jr, G D et al. (1992) The integrin alpha 6 beta 4 is a laminin receptor. J Cell Biol 117:671-8
Woo, H J; Lotz, M M; Jung, J U et al. (1991) Carbohydrate-binding protein 35 (Mac-2), a laminin-binding lectin, forms functional dimers using cysteine 186. J Biol Chem 266:18419-22

Showing the most recent 10 out of 14 publications